Expanding the OSD Toolbox: An Industry Approach to adsorb lipids onto powder substrates for Enhanced Dissolution of BCS Class II and IV APIs

Low-solubility drugs present major challenges in oral drug delivery, often limiting their therapeutic potential. In this insightful whitepaper, Alcami formulation development expert Bobby Sciscento delves into an innovative strategy to overcome these obstacles. Using furosemide—a classic BCS Class IV drug—as a model, he demonstrates how the incorporation of targeted excipients into solid dosage formulations can dramatically enhance dissolution rates and improve bioavailability.

In this whitepaper, you will learn:

• Innovative strategies to enhance drug solubility and bioavailability by leveraging cutting-edge formulation techniques, demonstrated using furosemide as a model compound.
• The impact of lipids and surfactants in oral solid dosage formulations and how their incorporation can significantly improve dissolution rates.
• Solutions for overcoming challenges with BCS Class II and IV drugs, focusing on low-solubility, low-permeability compounds.
• How self-emulsifying drug delivery systems (SEDDS) can create stable emulsions to enhance solubilization and drug release in the GI tract.
• The potential to develop versatile platform technologies for poorly soluble drugs, adaptable across multiple dosage formats for improved patient outcomes.